EUVIMEDObjevte EUVIMED
Multizentrische StudieKohortenstudie

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study

Alba López-Bravo iD, Ane Mínguez-Olaondo, Candela Nieves-Castellanos, Marta Ruibal-Salgado, Noemí Morollón Sánchez-Mateos iD, María Pilar Navarro-Pérez iD, Alicia Alpuente, Marta Torres-Ferrús, Jésica García-Ull, Ana Gago-Veiga, David García-Azorín iD, Alicia González-Martínez iD and 2 more

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14913 ↗

At a glance

Multizentrische Studie in Headache: The Journal of Head and Face Pain, 2025. Written by Alba López-Bravo and 13 co-authors. Institution: Neurology Department, Hospital Reina Sofia, Tudela, Navarra, Spain. Major MEDLINE topics: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Migraine Disorders. Cited 5 times so far (Crossref); 32 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are the first migraine‐specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited.

Methods

A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six‐item Headache Impact Test (HIT‐6) scores were collected. Patients’ satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM‐1.4©).

Results

A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM‐1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0–83.3) and 83.3 (61.1–88.9) for effectiveness, 83.3 (72.2–100) and 83.3 (77.8–100) for convenience, and finally, a score of 78.6 (50.0–92.9) and 85.7 (71.4–92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0–17.0; p < 0.001) and 8.0 (4.0–12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0–17.0; p < 0.001) and 9.0 (5.0–17.0; p < 0.001) days after 6 months. The median (IQR) HIT‐6 score decreased from 68.0 (65.0–72.0) to 60.0 (51.0–66.0; p < 0.001) at Month 3 and to 56.0 (48.0–64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0–120.0) to 24 (7.8–60.0; p < 0.001) and 17 (5.0–45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 ( β = −0.93, 95% CI −1.34 to −0.53; p < 0.001) and 6 months ( β = −1.56, 95% CI −2.15 to −0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire ( β = −0.82, 95% CI −1.27 to −0.37; p < 0.001) and ( β = −1.80, 95% CI −2.42 to −1.18; p < 0.001).

Conclusions

Most patients were satisfied with CGRP mAbs’ effectiveness, tolerability, and convenience in a real‐world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideMigraine DisordersOutcome Assessment, Health CarePatient SatisfactionAdultFemaleHumansMaleMiddle AgedCohort StudiesProspective Studies

Author keywords

calcitonin gene‐related peptidemigrainepatient satisfactionreal‐worldtreatment satisfaction

Substances

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptideerenumabfremanezumabgalcanezumab

Authors and institutions

  • Neurology Department, Hospital Reina Sofia, Tudela, Navarra, Spain.
  • Aragon Institute for Health Research (IIS Aragón), Zaragoza, Spain.
  • Department of Health Sciences, Public University of Navarra, Pamplona, Spain.
  • Neurology Department, Hospital Universitario Donostia, San Sebastian, Spain.
  • Neurology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
  • Headache and Neuralgia Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

ORCID profiles: Alba López-Bravo, Noemí Morollón Sánchez-Mateos, María Pilar Navarro-Pérez, David García-Azorín, Alicia González-Martínez, Sonia Santos-Lasaosa

Cite

APA

López-Bravo, A., Mínguez-Olaondo, A., Nieves-Castellanos, C., Ruibal-Salgado, M., Sánchez-Mateos, N. M., Navarro-Pérez, M. P., Alpuente, A., Torres-Ferrús, M., García-Ull, J., Gago-Veiga, A., García-Azorín, D., González-Martínez, A., Sierra, Á., & Santos-Lasaosa, S. (2025). Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14913

Vancouver

López-Bravo A, Mínguez-Olaondo A, Nieves-Castellanos C, Ruibal-Salgado M, Sánchez-Mateos NM, Navarro-Pérez MP, et al. Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14913

BibTeX
@article{LpezBravo2025,
  author = {López-Bravo, Alba and Mínguez-Olaondo, Ane and Nieves-Castellanos, Candela and Ruibal-Salgado, Marta and Sánchez-Mateos, Noemí Morollón and Navarro-Pérez, María Pilar and Alpuente, Alicia and Torres-Ferrús, Marta and García-Ull, Jésica and Gago-Veiga, Ana and García-Azorín, David and González-Martínez, Alicia and Sierra, Álvaro and Santos-Lasaosa, Sonia},
  title = {Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14913}
}
Start for free →